Jeffrey Dierks - 24 Jan 2025 Form 4 Insider Report for Harmony Biosciences Holdings, Inc. (HRMY)

Signature
/s/ Christian Ulrich, Attorney-in-Fact
Issuer symbol
HRMY
Transactions as of
24 Jan 2025
Net transactions value
-$188,983
Form type
4
Filing time
28 Jan 2025, 16:08:45 UTC
Previous filing
21 Jan 2025
Next filing
05 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRMY Common Stock Options Exercise $402,806 +13,125 $30.69 13,125 24 Jan 2025 Direct
transaction HRMY Common Stock Sale $295,531 -8,000 -61% $36.94 5,125 24 Jan 2025 Direct F1, F2
transaction HRMY Common Stock Sale $194,103 -5,125 -100% $37.87 0 24 Jan 2025 Direct F1, F3
transaction HRMY Common Stock Options Exercise $0 +2,687 $0.000000 2,687 24 Jan 2025 Direct
transaction HRMY Common Stock Tax liability $40,215 -1,058 -39% $38.01 1,629 24 Jan 2025 Direct F4
transaction HRMY Common Stock Sale $61,941 -1,629 -100% $38.02 0 27 Jan 2025 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRMY Stock Option Options Exercise $0 -13,125 -25% $0.000000 39,375 24 Jan 2025 Common Stock 13,125 $30.69 Direct F6
transaction HRMY Restricted Stock Units Options Exercise $0 -2,687 -25% $0.000000 8,063 24 Jan 2025 Common Stock 2,687 Direct F7
transaction HRMY Stock Option Award $0 +47,200 $0.000000 47,200 25 Jan 2025 Common Stock 47,200 $38.01 Direct F8
transaction HRMY Restricted Stock Units Award $0 +13,450 $0.000000 13,450 25 Jan 2025 Common Stock 13,450 Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.485 to $38.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.40. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F7 This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F8 The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F9 The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.